Our data on the restraining ability of the RAGE inhibitors FPS-ZM1 and RAP in BC cells, in animal models, as well as in patient-derived samples provides solid pre-clinical validation on the feasibility of anti-RAGE strategies in breast malignancies during hyperinsulinemia. This evidence concerns the gene AGER and Hyperinsulinemia.